A Miracle-Like Gene-Editing That People will Sooner or Later Recognize.
The Wellcome Sanger Institute’s new findings about CRISPR/Cas9 gene editing is intended to lead to further improvement in the safety of the breakthrough CRISPR gene editing procedure before it is used in clinical practice; the information is not intended to condemn it. Unfortunately, innocent investors got panicky when they heard the Wellcome Sanger findings, which were published in the journal Nature Biotechnology. Investors’ response to the article was an uncalled-for selloff of the stocks of the firms that created . . .